Highland Therapeutics Inc., a Toronto, CA-based specialty pharmaceutical company, completed a US$6.7m funding.
Investors included Highland’s Clinical Development group – an entity responsible for the manufacturing and clinical development of the company’s two lead compounds.
Led by David Lickrish, President and CEO, Highland Therapeutics leverages its proprietary technologies to optimize the delivery of previously approved drug products. The company’s lead products, HLD-100 and HLD-200, are novel formulations of the psychostimulants (amphetamine and methylphenidate, respectively) used to treat ADHD and are being developed to treat the lack of symptom control during the early morning routine.
The company intends to use the funds to:
– conduct up to five clinical studies with its two lead compounds – HLD-100 (a novel formulation of amphetamine) and HLD-200 (a novel formulation of methylphenidate), both being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder (ADHD),
– conduct market research to further develop commercialization strategies for the drug candidates,
– scale-up manufacturing activities, and
– use for general corporate purposes.